2013
DOI: 10.3111/13696998.2012.761633 View full text |Buy / Rent full text
|
|

Abstract: A core economic model was successfully adapted locally by several countries. The model showed that posaconazole was cost-saving or cost-effective vs fluconazole/itraconazole and led to positive reimbursement listings.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
4
0

Publication Types

Select...

Relationship

0
0

Authors

Journals